Physician profile
Andras Peter
NPI 1154344646
$8,011.49
in general payments reported to CMS, 2019-2025
26 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,044 · 2020: $600 · 2021: $1,762 · 2022: $492 · 2023: $1,054 · 2024: $736 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,920.27 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Alkermes, INC. | $1,833.72 | 2019-2024 | Vivitrol |
| Intuitive Surgical, INC. | $825.43 | 2021 | |
| Abbvie INC. | $700.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $668.86 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $322.37 | 2019-2024 | Verquvo, Dificid |
| Gilead Sciences, INC. | $304.11 | 2019-2024 | Epclusa |
| Pfizer INC. | $212.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.95 | 2019-2025 | Jardiance |
| Indivior INC. | $151.10 | 2019-2025 | Sublocade |
| Exact Sciences Corporation | $144.31 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $139.53 | 2019-2020 | |
| Eisai INC. | $108.59 | 2019-2021 | |
| Braeburn INC. | $82.68 | 2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $68.00 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $67.55 | 2019-2021 | |
| Lilly USA, LLC | $54.53 | 2020-2021 | |
| Abbott Laboratories | $53.24 | 2021 | |
| Genentech USA, INC. | $41.13 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $29.33 | 2019 | |
| Novo Nordisk INC | $28.00 | 2020 | |
| Verona Pharma, INC. | $16.93 | 2025 | Ohtuvayre |
| Daiichi Sankyo INC. | $14.16 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $14.08 | 2019 | |
| Kaleo, INC. | $11.46 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andras Peter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.